RESUMEN
The Coronavirus disease (COVID-19) pandemic is disrupting our health environment. As expected, studies highlighted the great susceptibility of cancer patients to COVID-19 and more severe complications, leading oncologists to deeply rethink patient cancer care. This review is dedicated to the optimization of care pathways and therapeutics in cancer patients during the pandemic and aims to discuss successive issues. First we focused on the international guidelines proposing adjustments and alternative options to cancer care in order to limit hospital admission and cytopenic treatment in cancer patients, most of whom are immunocompromised. In addition cancer patients are prone to polypharmacy, enhancing the risk of drug-related problems as adverse events and drug-drug interactions. Due to increased risk in case of COVID-19, we reported a comprehensive review of all the drug-related problems between COVID-19 and antineoplastics. Moreover, in the absence of approved drug against COVID-19, infected patients may be included in clinical trials evaluating new drugs with a lack of knowledge, particularly in cancer patients. Focusing on the several experimental drugs currently being evaluated, we set up an original data board helping oncologists and pharmacists to identify promptly drug-related problems between antineoplastics and experimental drugs. Finally additional and concrete recommendations are provided, supporting oncologists and pharmacists in their efforts to manage cancer patients and to optimize their treatments in this new era related to COVID-19.
Asunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/inmunología , Oncología Médica/normas , Neoplasias/tratamiento farmacológico , Neoplasias/inmunología , Farmacia/normas , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/inmunología , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Betacoronavirus/aislamiento & purificación , COVID-19 , Ensayos Clínicos como Asunto/métodos , Ensayos Clínicos como Asunto/normas , Infecciones por Coronavirus/virología , Humanos , Oncología Médica/métodos , Neoplasias/virología , Pandemias , Farmacia/métodos , Neumonía Viral/virología , Guías de Práctica Clínica como Asunto , SARS-CoV-2RESUMEN
Antineoplastic drug induced nausea and vomiting are common adverse events in cancer care of paediatric patients ; therefore, prevention and management of these adverse events is a major concern for healthcare professionals. There are common features between paediatric and adult patients in terms of the emetogenic level depending on antineoplastic agents or about available medicines. However, there are also specificities for paediatric population including individual risk factors of emesis or nausea assessment for example. Knowledge relative to available medicines is also limited in the paediatric population, especially for recent medicines. This review aims to provide a comprehensive overview about antiemetics in paediatric oncology to clinicians and other healthcare professionals involved in paediatric cancer care. First of all, we describe physiopathological paediatric specificity, risk factors and clinical assessment of antineoplastic drug induced nausea and vomiting. Secondly, we focus on available medicines and also address the issue of complementary and alternative medicines.
Asunto(s)
Antieméticos/uso terapéutico , Antineoplásicos/efectos adversos , Náusea/terapia , Neoplasias/tratamiento farmacológico , Vómitos/terapia , Terapia por Acupuntura/métodos , Corticoesteroides/uso terapéutico , Aromaterapia/métodos , Niño , Humanos , Náusea/inducido químicamente , Náusea/clasificación , Náusea/prevención & control , Fitoterapia/métodos , Factores de Riesgo , Vómitos/inducido químicamente , Vómitos/clasificación , Vómitos/prevención & controlRESUMEN
Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs). These interactions can occur among antineoplastic, ongoing chronic treatment(s) and chemotherapy-associated treatments, like antiemetics. Clinically relevant interactions based on enzyme- or transporter-inhibition phenomena of active drugs can increase the frequency of their DDIs. We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations. We discuss this DDI's hypothetical pharmacological mechanisms and management.
Asunto(s)
Aprepitant/farmacología , Sueños/efectos de los fármacos , Alucinaciones/inducido químicamente , Opio/farmacología , Polifarmacia , Adenocarcinoma/tratamiento farmacológico , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Aprepitant/uso terapéutico , Artralgia/tratamiento farmacológico , Camptotecina/efectos adversos , Camptotecina/análogos & derivados , Interacciones Farmacológicas , Fluorouracilo/efectos adversos , Humanos , Leucovorina/efectos adversos , Masculino , Náusea/inducido químicamente , Náusea/prevención & control , Opio/uso terapéutico , Polvos , Neoplasias del Colon Sigmoide/tratamiento farmacológicoRESUMEN
Background The role of olanzapine in the treatment of chemotherapy-induced nausea and vomiting (CINV) in addition to the antiemetic therapeutic combination with aprepitant, setrons, and corticosteroids has not been well defined. Objective To investigate the effectiveness of the addition of olanzapine to a standard triplet therapy for the prevention of CINV in patients who experienced CINV during their first chemotherapy course, despite receiving a well-managed prevention protocol. Setting One comprehensive cancer centre in France. Method In a retrospective study with comparator, patients with a high risk of emesis were assigned to two groups during two different 6-month periods, before and after the introduction of olanzapine in clinical practice, respectively. In the olanzapine group, the antiemetic protocol for the second course of chemotherapy was reinforced by the addition of olanzapine at 5 mg/day from day 1 to 5 in contrast with the control group. Main outcome measure The proportion of patients who experienced neither nausea nor emesis during the delayed phase (24-120 h). Results The 25 patients in each group exhibited comparable characteristics and emetic chemotherapy level. During the first course, no significant difference was observed. During the second course, nausea and vomiting were ameliorated in 12 patients in the olanzapine group and 4 patients in the control group (p < 0.05). Nausea (12 vs. 4, p < 0.05) and vomiting (18 vs. 11, p < 0.05) also significantly improved. In the OLZ group, no adverse event was linked to olanzapine use. Conclusion The addition of olanzapine was observed to effectively restore CINV prevention in patients who did not respond to standard antiemetic therapy.